Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.
Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H. Namisaki T, et al. Among authors: okura y. Eur J Gastroenterol Hepatol. 2017 Jan;29(1):23-30. doi: 10.1097/MEG.0000000000000765. Eur J Gastroenterol Hepatol. 2017. PMID: 27755231
von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H. Takaya H, et al. Among authors: okura y. United European Gastroenterol J. 2018 Nov;6(9):1401-1409. doi: 10.1177/2050640618779660. Epub 2018 May 25. United European Gastroenterol J. 2018. PMID: 30386613 Free PMC article.
Identification of clinical risk factors for histological progression of primary biliary cholangitis.
Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H. Fujinaga Y, et al. Among authors: okura y. Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14. Hepatol Res. 2019. PMID: 31021038
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H. Namisaki T, et al. Among authors: okura y. J Gastroenterol. 2016 Feb;51(2):162-72. doi: 10.1007/s00535-015-1104-x. Epub 2015 Jul 21. J Gastroenterol. 2016. PMID: 26190501
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H. Nishimura N, et al. Among authors: okura y. J Gastroenterol. 2016 Dec;51(12):1141-1149. doi: 10.1007/s00535-016-1200-6. Epub 2016 Mar 29. J Gastroenterol. 2016. PMID: 27025708
Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis.
Namisaki T, Moriya K, Noguchi R, Kitade M, Kawaratani H, Yamao J, Mitoro A, Yoshida M, Sawai M, Uejima M, Mashitani T, Takeda K, Okura Y, Kaji K, Takaya H, Aihara Y, Douhara A, Nishimura N, Sawada Y, Sato S, Seki K, Yoshiji H. Namisaki T, et al. Among authors: okura y. Hepatol Res. 2017 Mar;47(3):E178-E186. doi: 10.1111/hepr.12746. Epub 2016 Jul 21. Hepatol Res. 2017. PMID: 27189879 No abstract available.
Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Nishimura N, Takaya H, Aihara Y, Sawada Y, Sato S, Seki K, Mitoro A, Yamao J, Yoshiji H. Kawaratani H, et al. Among authors: okura y. Hepatol Res. 2017 Aug;47(9):854-861. doi: 10.1111/hepr.12826. Epub 2016 Nov 9. Hepatol Res. 2017. PMID: 27704665
DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis.
Asada K, Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Takeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N, Seki K, Mitoro A, Yamao J, Yoshiji H. Asada K, et al. Among authors: okura y. World J Hepatol. 2016 Oct 8;8(28):1194-1199. doi: 10.4254/wjh.v8.i28.1194. World J Hepatol. 2016. PMID: 27729955 Free PMC article.
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
Okura Y, Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Noguchi R, Nishimura N, Seki K, Kawaratani H, Takaya H, Sato S, Sawada Y, Shimozato N, Furukawa M, Nakanishi K, Saikawa S, Kubo T, Asada K, Yoshiji H. Okura Y, et al. Hepatol Res. 2017 Nov;47(12):1317-1328. doi: 10.1111/hepr.12860. Epub 2017 Feb 13. Hepatol Res. 2017. PMID: 28029729
288 results